JP2012528185A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012528185A5 JP2012528185A5 JP2012513239A JP2012513239A JP2012528185A5 JP 2012528185 A5 JP2012528185 A5 JP 2012528185A5 JP 2012513239 A JP2012513239 A JP 2012513239A JP 2012513239 A JP2012513239 A JP 2012513239A JP 2012528185 A5 JP2012528185 A5 JP 2012528185A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hydrogen
- methyl
- cancer
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 125000001153 fluoro group Chemical group F* 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 150000002222 fluorine compounds Chemical class 0.000 claims 1
- 0 *C(*)(c1nnc2[s]c(C3=C*N=C3*)n[n]12)c(c(*)c1)c(*)c2c1nccc2 Chemical compound *C(*)(c1nnc2[s]c(C3=C*N=C3*)n[n]12)c(c(*)c1)c(*)c2c1nccc2 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- -1 [1,3,4] thiadiazol-3-yl Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18178409P | 2009-05-28 | 2009-05-28 | |
| US61/181,784 | 2009-05-28 | ||
| PCT/US2010/036309 WO2010138663A1 (en) | 2009-05-28 | 2010-05-27 | Substituted pyrazole inhibitors of c-met protein kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012528185A JP2012528185A (ja) | 2012-11-12 |
| JP2012528185A5 true JP2012528185A5 (OSRAM) | 2013-07-11 |
Family
ID=42370912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513239A Pending JP2012528185A (ja) | 2009-05-28 | 2010-05-27 | ｃ−Ｍｅｔタンパク質キナーゼの置換ピラゾール阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8269012B2 (OSRAM) |
| EP (1) | EP2435444A1 (OSRAM) |
| JP (1) | JP2012528185A (OSRAM) |
| CN (1) | CN102448968A (OSRAM) |
| AU (1) | AU2010254053A1 (OSRAM) |
| CA (1) | CA2762186A1 (OSRAM) |
| MX (1) | MX2011012522A (OSRAM) |
| WO (1) | WO2010138663A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2435443B1 (en) * | 2009-05-28 | 2013-07-31 | Vertex Pharmaceuticals Incorporated | Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase |
| ES2712717T3 (es) * | 2012-07-27 | 2019-05-14 | Sato Pharma | Compuesto de difluorometileno |
| CN103073491A (zh) * | 2013-01-25 | 2013-05-01 | 桑迪亚医药技术（上海）有限责任公司 | 一种2-（5,7-二氟-6-喹啉基）乙酸/丙酸（酯）的合成方法 |
| CN106924260B (zh) * | 2015-12-31 | 2018-05-25 | 北京浦润奥生物科技有限责任公司 | 化合物在制备用于治疗脑胶质瘤的药物中的用途 |
| GR1009565B (el) * | 2016-07-14 | 2019-08-06 | Galenica Α.Ε. | Νεα παραγωγα 1,2,4-τριαζολο-[3,4-b]-1,3,4-θειαδιαζολιων |
| CN109897054B (zh) * | 2017-12-08 | 2021-12-10 | 中国药科大学 | 三唑并噻二唑类c-Met激酶抑制剂的制备方法及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003000660A1 (fr) * | 2001-06-22 | 2003-01-03 | Kirin Beer Kabushiki Kaisha | Derive de quinoleine et derive de quinoleine permettant d'inhiber l'auto-phosphorylation du recepteur des proliferateurs des hepatocytes, ainsi que des compositions medicinales contenant ce derive |
| EP1713484A2 (en) * | 2004-01-23 | 2006-10-25 | Amgen Inc. | Compounds and methods of use |
| ATE492544T1 (de) * | 2004-08-26 | 2011-01-15 | Pfizer | Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer |
| NZ568666A (en) * | 2005-11-30 | 2011-09-30 | Vertex Pharma | [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole derivative as inhibitors of c-Met |
| CA2688823A1 (en) * | 2007-05-21 | 2008-11-27 | Sgx Pharmaceuticals, Inc. | Heterocyclic kinase modulators |
| AU2009316756B2 (en) * | 2008-11-19 | 2016-02-25 | Vertex Pharmaceuticals Incorporated | A triazolothiadiazole inhibitor of c-Met protein kinase |
| EP2435443B1 (en) * | 2009-05-28 | 2013-07-31 | Vertex Pharmaceuticals Incorporated | Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase |
-
2010
- 2010-05-27 EP EP10730618A patent/EP2435444A1/en not_active Withdrawn
- 2010-05-27 JP JP2012513239A patent/JP2012528185A/ja active Pending
- 2010-05-27 WO PCT/US2010/036309 patent/WO2010138663A1/en not_active Ceased
- 2010-05-27 CN CN2010800231025A patent/CN102448968A/zh active Pending
- 2010-05-27 US US12/788,608 patent/US8269012B2/en not_active Expired - Fee Related
- 2010-05-27 CA CA2762186A patent/CA2762186A1/en not_active Abandoned
- 2010-05-27 MX MX2011012522A patent/MX2011012522A/es not_active Application Discontinuation
- 2010-05-27 AU AU2010254053A patent/AU2010254053A1/en not_active Abandoned
- 2010-05-27 US US12/788,715 patent/US8269013B2/en active Active
-
2012
- 2012-09-17 US US13/621,396 patent/US20130018072A1/en not_active Abandoned